Sunitinib treatment in rats during organogenesis resulted in developmental effects at ≥ 5 mg/ kg/ day consisting of increased incidence of foetal skeletal malformations, predominantly characterized as retarded ossification of thoracic/ lumbar vertebrae and occurred at plasma exposure levels 6-fold higher than is observed in clinic.
56 rinna - / nimmeosa luustumise pidurdumisega ja see esines plasmakontsentratsioonide puhul, mis olid 6 korda suuremad, kui kliinilistes tingimustes.